Luca Paruzzo

966 total citations
12 papers, 192 citations indexed

About

Luca Paruzzo is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Luca Paruzzo has authored 12 papers receiving a total of 192 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Luca Paruzzo's work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Protein Degradation and Inhibitors (3 papers). Luca Paruzzo is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Protein Degradation and Inhibitors (3 papers). Luca Paruzzo collaborates with scholars based in Italy, United States and Netherlands. Luca Paruzzo's co-authors include Umberto Vitolo, Mattia Novo, Marco Ruella, Massimo Aglietta, Daniela Caravelli, Fabrizio Carnevale‐Schianca, Emanuela Colombo, Pier Giuseppe Pelicci, Corrado Tarella and Susanna Gallo and has published in prestigious journals such as Nature Protocols, Cancer Treatment Reviews and Cancers.

In The Last Decade

Luca Paruzzo

12 papers receiving 191 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luca Paruzzo Italy 6 99 71 58 47 33 12 192
Teresa Laguna Spain 9 86 0.9× 106 1.5× 40 0.7× 51 1.1× 41 1.2× 11 254
Esperanza Martín‐Sánchez Spain 9 65 0.7× 118 1.7× 57 1.0× 44 0.9× 26 0.8× 21 224
A. Rosenwald Germany 5 85 0.9× 72 1.0× 81 1.4× 50 1.1× 14 0.4× 10 173
Andrej Lissat Germany 7 43 0.4× 94 1.3× 31 0.5× 25 0.5× 55 1.7× 17 181
Fenglin Zang China 10 71 0.7× 92 1.3× 33 0.6× 48 1.0× 45 1.4× 22 211
Shyamprasad Deraje Vasudeva United States 5 73 0.7× 142 2.0× 38 0.7× 19 0.4× 66 2.0× 8 229
Zachary Crees United States 9 69 0.7× 98 1.4× 38 0.7× 26 0.6× 15 0.5× 34 199
Tupitsyn Nn Russia 7 87 0.9× 43 0.6× 21 0.4× 50 1.1× 21 0.6× 74 195
Chun Jin China 12 83 0.8× 194 2.7× 33 0.6× 51 1.1× 40 1.2× 15 291
Lucie Heinzerling Germany 8 146 1.5× 70 1.0× 17 0.3× 51 1.1× 52 1.6× 22 210

Countries citing papers authored by Luca Paruzzo

Since Specialization
Citations

This map shows the geographic impact of Luca Paruzzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Paruzzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Paruzzo more than expected).

Fields of papers citing papers by Luca Paruzzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Paruzzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Paruzzo. The network helps show where Luca Paruzzo may publish in the future.

Co-authorship network of co-authors of Luca Paruzzo

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Paruzzo. A scholar is included among the top collaborators of Luca Paruzzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Paruzzo. Luca Paruzzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Ho, Matthew, et al.. (2025). Extramedullary Multiple Myeloma: Challenges and Opportunities. Current Oncology. 32(3). 182–182. 1 indexed citations
2.
Guruprasad, Puneeth, Shan Liu, Luca Paruzzo, et al.. (2025). Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. Nature Protocols. 20(12). 3629–3654. 1 indexed citations
3.
Sullivan, Ryan J., Anthony R. Cillo, Robert L. Ferris, et al.. (2025). SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 13(6). e011929–e011929. 1 indexed citations
4.
Yu, Kyle K., Matthew Ho, Luca Paruzzo, et al.. (2025). Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25. S64–S65. 1 indexed citations
5.
Chong, Elise A., Sunita D. Nasta, Daniel J. Landsburg, et al.. (2024). Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 30(7). 726.e1–726.e8. 4 indexed citations
6.
Ruella, Marco, et al.. (2024). Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia. Blood Cancer Discovery. 5(4). 234–248. 25 indexed citations
8.
Lee, Yong Gu, Patrizia Porazzi, Luca Paruzzo, et al.. (2023). Apoptosis: a Janus bifrons in T-cell immunotherapy. Journal for ImmunoTherapy of Cancer. 11(4). e005967–e005967. 16 indexed citations
9.
Avallone, Gianluca, Simone Ribero, Gabriele Roccuzzo, et al.. (2022). Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. Journal of Clinical Medicine. 11(3). 828–828. 19 indexed citations
10.
Novo, Mattia, et al.. (2022). Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treatment Reviews. 110. 102443–102443. 85 indexed citations
11.
Berrino, Enrico, Antonella Balsamo, Alberto Pisacane, et al.. (2021). High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. ESMO Open. 6(3). 100133–100133. 13 indexed citations
12.
Gallo, Susanna, Alessandro Zaccagna, Luca Paruzzo, et al.. (2020). Melanoma Brain Metastases in the Era of Target Therapies: An Overview. Cancers. 12(6). 1640–1640. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026